Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

Affiliations

• ¹ Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ² Precision Biologics, Inc, Bethesda, MD, USA. massimo.fantini@precision-biologics.com.
• ³ Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ⁴ Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ⁵ Precision Biologics, Inc, Bethesda, MD, USA.
• ⁶ Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. annunzic@mail.nih.gov.